References Chapter 10

  1. World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. 2011 Update. Geneva, Switzerland 2011.

  2. Dooley KE, Mitnick CD, DeGroote MA, et al. and on behalf of the Efficacy Subgroup, RESIST-TB. Old Drugs, New Purpose: Retooling Existing Drugs for Optimized Treatment of Resistant Tuberculosis. Clinical Infectious Diseases 2012;55(4):572–81.

  3. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46(4): 1022-5.

  4. Baohong JI, Nacer L, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset JH. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42:2006-2069.

  5. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs. 2007;67(14):2077-99.

  6. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, Lee J. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest. 2003 Oct;124(4):1476-81.

  7. US FDA. Highlights of prescribing information.

  8. World Health Organization. Interim guidance on the use of bedaquiline to treat MDR-TB. Geneva, 2013.

  9. Sundari Mase, Terence Chorba, Philip Lobue, Kenneth Castro. Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis. MMWR Recommendations and Reports, October 25, 2013 / 62(rr09);1-12.

  10. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008;134:187-92.

  11. Fortún J, Martín-Dávila P, Navas E, et al. Linezolid for the treatment of multidrugresistant tuberculosis. J Antimicrob Chemother 2005;56:180-5.

  12. Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006;58:701-4.

  13. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010;50:49-55.

  14. G Sotgiu, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. ERJ April 10, 2012.

  15. H. Cox, N. Ford: Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-454.

  16. Singla R, Caminero JA, Jaiswal A, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J 2012; 39: 956-962.

  17. Chang KC, Leung CC, Daley CL. Linezolid for multidrug-resistant tuberculosis. Lancet Infect Dis 2012; 12: 502-503.

  18. Lee M, Lee J, Carroll MW, et al. Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis. N Engl J Med 2012;367:1508-18.

  19. Katiyar SK, Bihari S, Prakash S, et al. A randomized controlled trial of high-dose isoniazid adjuvant therapy for multidrug-reisistant tuberculosis. Int J Tuberc Lung Dis 12(2): 139-145.

  20. Rom WN, Garay S, Eds. Tuberculosis. Philadelphia, Lippincott Williams & Wilkins; 2004. p 751.

  21. World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. 2008 Emergency Update. Geneva, Switzerland 2008.

  22. Nunn PP, Kibuga D, Gathua S, et al. Thiacetazone commonly causes cutaneous hypersensitivity reactions in HIV positive patients treated for tuberculosis. Lancet 1991; 337: 627-630.

  23. A Van Deun, Aung Kya Jai Maug, Md Abdul Hamid Salim, Pankaj Kumar Das, Mihir Ranjan Sarker, P Daru, and HL Rieder: Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis Am J Respir Crit Care Med Vol 182. pp 684–692, 2010.

  24. F Kassa, D Affolabi, G Ade, S Anagonou, M Gninafon, A Trebucq. Successful 12-month treatment for multidrug-resistant tuberculosis patients in Benin National TB Programme, Ministry of Health, Cotonou, Benin. Abstract PC-728-16 International U presented at the International Union Against Tuberculosis and Lung Disease Conference, Kuala Lumpur, Malaysia. November 2012.

  25. World Health Organization. The use of short regimens for treatment of multidrug-resistant tuberculosis.

  26. Francis RS, Curwen MP. Major surgery for pulmonary tuberculosis: final report. A national survey of 8232 patients operated on from April 1953 to March 1954 and followed up for five years. Tubercle 1964; supplement 45: 5-79.

  27. ED Chan, V Laurel, MJ Strand, JF Chan,Mai-Lan N. Huynh, M Goble, and MD Iseman: Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103–1109.

  28. Pomerantz, B., Cleveland, J., Olson, H., Pomernatz, M. Pulmonary resection for multidrugresistant tuberculosis. Journal of Thoracic and Cardiovascular Surgery 2001; 121(3): 448-53.

  29. Somocurcio J, Sotomayor A, Shin S et al. Surgical Therapy for Patients with Drug-Resistant Tuberculosis: Report of 121 Cases Receiving Community- Based Treatment in Lima, Peru. Thorax published online 23 Aug 2006.

  30. Kim H, Kang C, Kim Y et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J 2006; 28: 576–580.

  31. Holdiness MR. Cerebrospinal fluid pharmokinetics of antituberculoisis drugs. Clin Pharmacokinet 1985;10:532-534.

  32. Daley CL. Mycobacterium tuberculosis Complex. In: Antimicrobial Therapy and Vaccines. Yu VL, Merigan Jr, TC, Barriere, SL, editors., Philadelphia: Williams & Wilkins, 1999; pp. 531-536.

  33. Migliori GB et al. Extensively drug-resistant tuberculosis, Italy and Germany [letter]. In: Emerging Infectious Diseases [serial on the Internet], May 2007.

  34. Jeon CY, Hwang SH, Min JH, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008 Jan 1;46(1):42-9.

  35. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs – worldwide, 2000–2004. Morbidity and Mortality Weekly Report, 2006, 55(11):301–305.